Agreement to Distribute Electrochemical Blood Glucose Monitoring System
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Agreement to Distribute Electrochemical Blood Glucose Monitoring System

WALTHAM, Mass., Oct. 22, 1996-- Selfcare, Inc. (AMEX: SLF) announced that it has entered into a distribution agreement with LifeScan, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), pursuant to which LifeScan will distribute an advanced version of Selfcare's proprietary electrochemical blood glucose monitoring system. As previously announced, Selfcare recently received FDA clearance for a prior version of the system. The advanced version must receive FDA clearance before sales can commence in the United States.

As contemplated by the November 10, 1995 agreements between Selfcare and LifeScan, in connection with entering into the distribution agreement LifeScan has paid Selfcare a $7 million success fee, and an affiliate of LifeScan has converted its existing loans of approximately $13.7 million into 201,622 shares of Selfcare common stock. In addition, the LifeScan affiliate will also receive, for no additional consideration, further shares equal to 5% of all common stock issued by Selfcare pursuant to options and warrants that were outstanding as of November 10, 1995. The company estimates that the LifeScan affiliate will ultimately receive approximately 278,800 additional shares.

Selfcare, with facilities in Waltham, Massachusetts, Inverness, Scotland, Galway, Ireland, and Munich, Germany, is engaged in the development, manufacture and marketing of self-test diagnostic products for the diabetes, women's health and infectious disease markets.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities